Literature DB >> 32952972

A Retrospective Descriptive Study Characterizing Coronavirus Disease Epidemiology among People in the Kurdistan Region, Iraq.

Nawfal R Hussein1, Ibrahim A Naqid1, Zana Sidiq M Saleem2.   

Abstract

Entities:  

Keywords:  Coronavirus disease 2019 (COVID-19); Iraq; Kurdistan Region; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Year:  2020        PMID: 32952972      PMCID: PMC7485477          DOI: 10.4084/MJHID.2020.061

Source DB:  PubMed          Journal:  Mediterr J Hematol Infect Dis        ISSN: 2035-3006            Impact factor:   2.576


× No keyword cloud information.

To the editor

Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an emerging infectious disease that was identified in December 2019 in Wuhan, China.1 In February 2020, the first cases of COVID-19 were recorded in Southern Iraq. With the appearance of these cases, strict control measures were implemented in the Kurdistan Region. These measures included the closure of schools and universities, the closing of borders and airports, cancellation of public and religious gatherings, and mandatory quarantine for persons returning from traveling abroad and contacts of confirmed cases. Despite these measures, the first case of COVID-19 was diagnosed in the region on March 1, 2020. All individuals diagnosed with SARS-CoV-2 infection were admitted to designated COVID centers regardless of symptoms and were treated according to the Ministry of Health guidelines. This report describes the first three months of the SARS-CoV-2epidemic in the Kurdistan Region of Iraq, including the case fatality rate and the recovery rate and factors related to COVID-19-related deaths.

Materials and methods

Study setting

Patients included in this study were from the Kurdistan Region, Northern Iraq. The region borders on Turkey and Iran, which both have COVID-19 epidemics. This region, which comprises four cities: Erbil, Duhok Sulaymaniyah, and Halabja, has a total population of 5,816,000. A COVID center has been established in each city for the management and treatment of confirmed cases. As a national program, all data regarding COVID-19 are published and updated daily through the COVID-19 information center, a Regional Government of Kurdistan website.

Patients

Patients were defined as any individual with a positive SARS-CoV-2 polymerase chain reaction (PCR) test result regardless of the presence of symptoms. The PCR test was conducted in duplicate. A suspected patient was defined as an individual with acute respiratory illness who had either traveled to an area with person-to-person transmission of SARS-CoV-2 or had close contact with a confirmed case within 14 days before symptom onset. Individuals who returned from abroad or been in contact with confirmed cases were quarantined. Quarantine was defined as confining individuals in a dedicated facility. In quarantine, patients were examined clinically for signs and symptoms of COVID-19. Patients were tested by PCR at the beginning and the end of the quarantine period. On discharge from hospital or quarantine centers, they were instructed to remain in quarantine in their homes for a further14 days.

Treatment

All patients received two doses of oral hydroxychloroquine 400 mg on the first day, then 200 mg twice a day, and 75 mg oral oseltamivir twice a day for the duration of their stay in the COVID center. Some patients were prescribed antibiotics or other medications as needed. Recovery was defined as the disappearance of symptoms with negative SARS-CoV-2 reverse transcription (RT)-PCR results. Patients admitted to COVID centers were tested using RT-PCR twice a week. If the test was negative, it was repeated after 24 hours. Patients were considered cured when two RT-PCR results on two consecutive days were negative. The significance of differences between confirmed, recovered, and death cases were determined by Chi-square and Fisher’s exact tests. P values of < 0.05 were considered statistically significant. Ethical approval was obtained from the ethics committee in the College of Medicine, University of Zakho.

Results

In the Kurdistan Region, 64591 people were tested for SARS-CoV-2 using RT-PCR up to May 21, of whom 452 (0.7%) were positive. The patient characteristics are shown in Table 1. The majority of cases were diagnosed in two cities: Erbil and Sulaymaniyah (Of the patients, 49.1% were male, and 88.9% were below the age of 60 years (Table 1). The majority (80%) were asymptomatic. The most common symptoms were fever, dry cough, and shortness of breath. The time to recovery ranged from 7 to 32 days. The criteria for severity of COVID-19 were defined according to The Official Chinese Government Guide to Diagnosing and Treating the Novel Coronavirus (7th version).2
Table 1

Characteristics of patients with SARS-CoV-2 infection in Kurdistan Region, Iraq, March 1 to May 21, 2020 (N=452).

VariableFrequencyPercentage (%)
Sex
 Male22249.11
 Female23050.89
Age group (year)
 0–1912527.66
 20–3918039.82
 40–599721.46
 ≥605011.06
City
 Erbil23351.55
 Sulaymaniyah17839.38
 Duhok194.2
 Halabja224.87
Symptoms
 Fever439.51
 Dry cough5512.17
 Shortness of Breath306.64

Total452100

Case Distribution

Following the diagnosis of the first case on March 1, 2020, there was a steady increase in the number of cases. The highest rate of infection was recorded in Erbil (Table 2). The highest number of patients was recorded (44 patients) on April 6, 2020. These patients were interviewed, and it was discovered that they had all attended a funeral, which was forbidden under the social distancing rules that were in place. Case tracing led to the diagnosis of 129 funeral-related cases in Erbil city.
Table 2

Case fatality rate of SARS-CoV-2 infection in Kurdistan Region, Iraq, March 1 to May 21, 2020.

VariableNo. of confirmed casesFatality rate (%)P-value
Sex
 Male2223 (1.35)0.68
 Female2302 (0.87)
Age group (year)
 0–191250 (0)
 20–391800 (0)0.001
 40–59970 (0)
 ≥60505 (10)
City
 Erbil2331 (0.43)
 Sulaymaniyah1784 (2.25)0.32
 Duhok190 (0)
 Halabja220 (0)

Case fatality and recovery rates

Five of the confirmed cases (1.1%) died. Four of them had ischemic heart disease and hypertension. One patient had diabetes and chronic renal insufficiency. All five patients were over 60 years old and had a history of diabetes or ischemic heart diseases. The case fatality rate increased significantly with age (p=0.001) but not with sex (p=0.68) (Table 2). Meanwhile, 385/452 (85.18%) recovered. No association was found between age or sex and the recovery rate (Table 3).
Table 3

Characteristics associated with recovery from SARS-CoV-2 infection in Kurdistan Region, Iraq, March 1 to May 21, 2020.

VariableNo. of recoveryRecovery rate (%)P-value
Sex
 Male18949.090.98
 Female19650.91
Age group (year)
 0–1910828.05
 20–3915540.260.28
 40–598421.82
 ≥60389.87
City
 Erbil21054.55
 Sulaymaniyah13434.810.5
 Duhok194.94
 Halabja225.71

Discussion

In the Kurdistan Region of Iraq, 452 cases of SARS-CoV-2 infection were recorded between March 1 and May 21, 2020, and the highest incidence was in Erbil city. The higher rate might be related to Erbil’s location. The capital city shares a border with the Islamic Republic of Iran, the epicenter of infection in the Middle East. It has previously been reported that the incidence of both SARS-CoV and SARS-CoV-2 infections is higher in males than in females.3,4 However, in this study, their number did not differ according to sex. This is difficult to explain and might be due to the relatively small number of infected patients. More studies are needed to determine the reason for sex-related differences in the incidence of infection. During the study period, five patients died because of the infection. All of them had comorbidities, such as ischemic heart disease and diabetes in agreement with a study conducted in China, where cardiovascular diseases, diabetes millets, chronic obstructive pulmonary diseases, hypertension, and cancers were found as the main risk factors for death.5 Previous studies found that the case fatality rate increases with age, particularly in patients older than 60 years.6 In agreement with this, we found a significant association between age and case fatality rate, and all the patients who died were older than 60 years old. Case fatality rates vary according to country; for example, case fatality rates of 4%, 4–8%, and 1.2% have been reported in China,7 Italy,8 and Germany,9 respectively. In our study, the case fatality rate was 1.1%, while the recovery rate was 85%. The low case fatality rate and high cure rate in the Kurdistan Region may be partially attributable to the early diagnosis of the infection and the early initiation of treatment. The majority of cases were young or middle-aged adults. If a higher proportion of the infections had occurred among older adults, such as in Italy, the fatality rate would probably have been higher. Notably, the Kurdistan Region imposed physical distancing and health-education programs sooner than some other countries and some other parts of Iraq, and that may have played a role in the low case fatality rate. The case fatality rate in Kurdistan may increase as the epidemic progresses. Early pharmaceutical intervention may also have played a role in the high recovery rate. However, this should be interpreted with caution as our study did not test drug efficacy. The most common clinical features associated with the infection have been reported to be fever, dry cough, shortness of breath, rhinitis, and hemoptysis.10 In our study, the most common symptoms were fever (9.5%), dry cough (12%), and mild shortness of breath (6.5%); however, most patients were either asymptomatic or had mild symptoms. None of the patients in our study required mechanical ventilation. It has been shown that strict social distancing helped control the outbreak in this region.11,12 The highest number of patients was recorded in Erbil city on April 6. Interviewing those patients revealed that all attended a prohibited funeral. Tracing the persons attending the funeral resulted in the identification of 129 people who had become infected. Consequently, state-imposed community-wide containment was declared, including a state-imposed curfew, and which controlled the spread of the infection, and the number of cases declined. One of the limitations of our study was that centers used different definitions for the duration of recovery. In some centers, the length was calculated from the first positive PCR of the diagnosis to the first negative PCR of the recovery. In contrast, other centers used different approaches, such as the duration of hospital admission. Therefore, the calculation of the time to recovery and its relationship to age and sex could not be assessed. To conclude, a majority of the patients diagnosed with COVID-19 were in Erbil city and were asymptomatic. Most patients recovered without complications. The case fatality rate was low and increased with age. Comprehensive research is needed to investigate regional variation in virus strains, the role of host genetic factors, and immune responses in different populations
  10 in total

1.  Covid-19: Why Germany's case fatality rate seems so low.

Authors:  Ned Stafford
Journal:  BMJ       Date:  2020-04-07

2.  Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection.

Authors:  Rudragouda Channappanavar; Craig Fett; Matthias Mack; Patrick P Ten Eyck; David K Meyerholz; Stanley Perlman
Journal:  J Immunol       Date:  2017-04-03       Impact factor: 5.422

3.  Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).

Authors: 
Journal:  Chin Med J (Engl)       Date:  2020-05-05       Impact factor: 2.628

4.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  Cross-Country Comparison of Case Fatality Rates of COVID-19/SARS-COV-2.

Authors:  Morteza Abdullatif Khafaie; Fakher Rahim
Journal:  Osong Public Health Res Perspect       Date:  2020-04

Review 6.  Epidemiological and Clinical Aspects of COVID-19; a Narrative Review.

Authors:  Goodarz Kolifarhood; Mohammad Aghaali; Hossein Mozafar Saadati; Niloufar Taherpour; Sajjad Rahimi; Neda Izadi; Seyed Saeed Hashemi Nazari
Journal:  Arch Acad Emerg Med       Date:  2020-04-01

7.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

Review 8.  Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review.

Authors:  Sasmita Poudel Adhikari; Sha Meng; Yu-Ju Wu; Yu-Ping Mao; Rui-Xue Ye; Qing-Zhi Wang; Chang Sun; Sean Sylvia; Scott Rozelle; Hein Raat; Huan Zhou
Journal:  Infect Dis Poverty       Date:  2020-03-17       Impact factor: 4.520

9.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

10.  Analysis and forecast of COVID-19 spreading in China, Italy and France.

Authors:  Duccio Fanelli; Francesco Piazza
Journal:  Chaos Solitons Fractals       Date:  2020-03-21       Impact factor: 5.944

  10 in total
  5 in total

1.  The Mediterranean Journal of Hematology and Infectious Diseases: A New Milestone and a Hope for Researchers in Third World Countries.

Authors:  Nawfal R Hussein
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-05-01       Impact factor: 3.122

2.  The Risk of SARS-CoV-2 Reinfection in Duhok city, Kurdistan Region of Iraq.

Authors:  Nawfal R Hussein; Brisik H Rashad; Lokman A Almizori; Shawkat Sabri Yousif; Ahmed Tayar Sadeeq; Yaseen Rashad Abdulkareem; Alan Mobarek Mahmood; Zhiyan K Salih
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-05-01       Impact factor: 2.576

3.  Home management scheme for patients with severe covid-19 in Duhok city, Kurdistan region of Iraq: a possible role for family physicians.

Authors:  Nawfal R Hussein; Zana Sidiq M Saleem; Brisik H Rashad; Ibrahim A Naqid; Nashwan Ibrahim; Dildar H Musa; Nina D Khezaqia; Ahmed H Yousif
Journal:  J Family Med Prim Care       Date:  2021-11-29

4.  A rare case of absolute thrombocytopaenia in a COVID-19 patient: Case report.

Authors:  Ameen M Mohammad; Azri S H Sgery; Nawfal R Hussein
Journal:  Ann Med Surg (Lond)       Date:  2021-11-22

5.  A study of SARS-CoV-2 delta variant breakthrough infections and side effects of the Oxford-AstraZeneca vaccine.

Authors:  Nawfal R Hussein; Bizav Naji Rasheed; Ibrahim A Naqid; Arshed Mustafa Dirbaz; Zana Sidiq M Saleem; Nashwan Ibrahim; Dildar H Musa; Sulav Muslih Mohammed
Journal:  Public Health Pract (Oxf)       Date:  2022-07-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.